Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Nanjing University of Chinese Medicine · Nanjing General Hospital of Nanjing Military Command · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
469
total citations
- FWCI
- 87.91
- Percentile
- 100%
- References
- 43
Citations per year
Authors
209- SQShukui Qin
Nanjing University of Chinese Medicine, Nanjing General Hospital of Nanjing Military Command
- MCMinshan Chen
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- ACAnn‐Lii Cheng
National Taiwan University Hospital
- AOAhmed O. Kaseb
The University of Texas MD Anderson Cancer Center
- MKMasatoshi Kudo
Kindai University
Topics & keywords
Topics
Keywords
- Medicine
- Bevacizumab
- Atezolizumab
- Hazard ratio
- Clinical endpoint
- Population
- Internal medicine
- Hepatocellular carcinoma
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ELEli Lilly and Company
- AAstraZeneca
- RRoche
- GSGilead Sciences
- FHF. Hoffmann-La Roche
- EExelixis
- EPEA Pharma Co., Ltd.
- DMDuke-NUS Medical School
- YYuhan
- EEisai
- OPOno Pharmaceutical
- IIpsen
- SMSirtex Medical
- GGenentech
- CPChugai Pharmaceutical
- BKBayer Korea
- MRMedical Research Council
- NMNational Medical Research Council
- EKEisai Korea